Key facts
- MyCural Therapeutics’s last known valuation is $6.2M (Dec 2024).
- It has raised $1.1M; the latest was Early Stage VC ($420K) in Aug 2025.
- Notable investors include Nordic Mentor Network For Entrepreneurship, 3T Invest, Arcandis, ArnDahl, LiU Invest — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for MyCural Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for MyCural Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MyCural Therapeutics
Developer of novel cancer therapies intended to fight high-risk tumors. The company identifies drug candidates and develops methods to kill MYC-driven tumor cells while sparing normal cells, enabling healthcare workers to treat patients with cancer.
- Sector
- Healthcare
- HQ
- Uppsala, Sweden
- Founded
- 2022
- Employees
- 10
- Website
- mycural.com/
- Ownership
- Privately Held (backing)
MyCural Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MyCural Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MyCural Therapeutics in its N-PORT filings yet. We sweep new filings monthly.